Abstract:Abstract Background Endoscopic submucosal dissection (ESD) is an advanced luminal resection technique for dysplastic and early cancerous gastrointestinal (GI) tract neoplasms. By removing lesions en bloc, this method provides more accurate histopathologic evaluation of resection margins in comparison to endoscopic mucosal resection (EMR). Superior curative resection and lower recurrence rates over EMR have been shown in addition to the benefit of reduced morbidity and mortality compared to surgery. While ESD has become well-established in Asia and Europe, its adoption in North America – and in particular Canada – has been slowed by multiple technical and economic factors including a scarcity of infrastructure, institutional support, and standardized training. Additionally, reproduced Canadian data corroborating its known global efficacy is currently lacking. Aims Our aim was to evaluate clinical and technical outcomes in patients who underwent ESD of superficial GI tract neoplasms at a tertiary-care academic centre. Methods We conducted a retrospective single-centre cohort study at The Centre for Advanced Therapeutic Endoscopy & Endoscopic Oncology, St. Michael’s Hospital, Toronto, Canada. Consecutive adults (age ampersand:003E 18) who underwent ESD of any superficial GI tract neoplasm from October 2017 to December 2022 were included in the study. Primary outcomes were rates of en bloc, complete (R0), and curative resections. Secondary outcomes were rates of recurrence and adverse events. Data was collected through electronic chart review. Results ESD was performed in a total of 308 lesions with a mean size of 2.5 cm (range, 1-7 cm). Gastric ESD was the most common (n=130), followed by esophageal (n=91), rectal (n=62), and colonic (n=22). Three patients underwent duodenal ESD. En bloc, R0, and curative resection rates were 89.2%, 84.7%, and 71.8%, respectively. 64.3% of lesions were cancerous on pathology (n=198), of which 48 had at least submucosal invasion. Rates of delayed bleeding and deep mural injury (DMI) requiring surgical intervention were 3.9% and 1.3%, respectively. Overall recurrence at the first surveillance endoscopy (SE1) was 3.6%. Conclusions En bloc, R0, and curative resection rates reported from this largest single-centre Canadian ESD cohort are comparable to existing North American data. Low rates of early recurrence and an adequate safety profile have been demonstrated with this emerging oncologic method of resection. Additional investigation is warranted to optimize lesion selection and determine long-term clinical outcomes to further establish this technique in the management of superficial GI tract neoplasms. Table I. Procedural characteristics, outcomes, and adverse events for patients who underwent ESD of superficial GI tract neoplasms. Funding Agencies None

Evaluation of the efficacy and tolerability of oral terbinafine (Daskil®) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator‐blinded, placebo‐controlled trial

Endoscopic Submucosal Dissection for Esophageal Squamous Cell Neoplasms.

Endoscopic Submucosal Dissection for Esophageal Cancer: Current and Future

A Recent Argument for the Use of Endoscopic Submucosal Dissection for Early Gastric Cancers

Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer

Sa1585 Long-Term Clinical Evaluation of Endoscopic Submucosal Dissection for Early Gastric Neoplasms

Endoscopic Submucosal Dissection for Early Esophageal Carcinomas and Pre-Malignant Lesions

Evaluation of endoscopic submucosal dissection for early esophageal cancers and precancerous lesion

A129 OUTCOMES FOLLOWING ENDOSCOPIC SUBMUCOSAL DISSECTION OF SUPERFICIAL GASTROINTESTINAL TRACT NEOPLASTIC LESIONS FROM A TERTIARY-CARE ACADEMIC CENTRE

Endoscopic Submucosal Dissection for Treatment of Esophageal Submucosal Tumors Originating from the Muscularis Propria Layer

Endoscopic Submucosal Dissection Used for Treating Early Neoplasia of the Foregut Using a Combination of Knives

Esophageal Stricture Prevention after Endoscopic Submucosal Dissection

Endoscopic Submucosal Dissection for Colorectal Epithelial Neoplasm

Endoscopic Submucosal Dissection for Colonic Lesions: Why and How Should We Do It?

Endoscopic Submucosal Dissection (ESD) in North America: A Large Prospective Multicenter Study.

Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection

Endoscopic Submucosal Dissection: A Safe and Effective Alternative to Surgical Intervention for Esophageal Hemangioma

Endoscopic submucosal dissection for suspected early gastric cancer: absolute versus expanded criteria in a large Western cohort (with video)

Endoscopic submucosal dissection for early esophageal squamous cell carcinoma: long-term results from a Western cohort

Application of Endoscopic Submucosal Dissection (ESD) in Treatment of Gastrointestinal Lesions-Single Center Experience

Clinical Analysis of Endoscopic Submucosal Dissection for the Synchronous Multiple Primary Early Cancers in Esophagus and Stomach: 12 Cases Report